Clarus Signs an Exclusive WW License Agreement with McGill University to Develop and Commercialize its Technology for Rare Conditions Due to Coenzyme-Q10 Deficiencies

 Clarus Signs an Exclusive WW License Agreement with McGill University to Develop and Commercialize its Technology for Rare Conditions Due to Coenzyme-Q10 Deficiencies

Clarus Signs an Exclusive WW License Agreement with McGill University to Develop and Commercialize its Technology for Rare Conditions Due to Coenzyme-Q10 Deficiencies

Shots:

  • McGill to receive $350,000 up front, $10.5M as development and regulatory milestone & is also eligible for ~$30M as a commercial milestone. Clarus will develop and commercialize McGill’s technology targeted the conditions associated with CoQ10 deficiencies
  • The collaboration will accelerate the development of potential treatments for rare, endocrine, metabolic, and neurological conditions associated with primary and secondary ubiquinone deficiencies belong to a broader class of mitochondrial diseases
  • The collaboration also broadens Clarus’ focus beyond androgen-based medicines to a metabolic therapy for CoQ10 deficiencies

Click here to­ read full press release/ article | Ref: Globe Newswire | Image: PR Newswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post